Exploring biomarkers in patients with advanced colorectal cancer receiving combined immunotherapy and anti-angiogenic treatment
A Biomarker Exploratory Study of Efficacy and Prognosis of Dual Blockade of PD1/PDL1 and CTLA4 in Combination of Anti-angiogenic Treatment in MSS Metastatic Colorectal Cancers and MSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
This study is testing if combining two types of immunotherapy with an anti-cancer treatment can help people with advanced colorectal cancer who haven't responded to other therapies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking University Cancer Hospital & Institute Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06549907 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with MSS metastatic colorectal cancer and MSI solid tumors that are resistant to PD-1/PD-L1 antibody monotherapy. It aims to identify clinical characteristics and biomarkers linked to the effects of dual PD1/PDL1 and CTLA4 blockade combined with anti-angiogenic therapy. The research will involve collecting various biological samples and utilizing multi-omics approaches, including single-cell sequencing and MRI imaging, to assess treatment responses over time. The study is conducted at Peking University Cancer Hospital, where patients will be monitored for clinical-pathological features and therapeutic outcomes.
Who should consider this trial
Good fit: Ideal candidates include individuals with pathologically confirmed MSS metastatic colorectal cancers or MSI solid tumors that have not responded to PD-1/PD-L1 antibody monotherapy.
Not a fit: Patients with active malignancies outside the gastrointestinal system may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with difficult-to-treat colorectal cancers.
How similar studies have performed: While similar approaches have been explored, this specific combination of therapies and multi-omics analysis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pathologically confirmed MSS metastatic colorectal cancers or MSI solid tumors refractory to PD1/PDL1 antibody monotherapy * Receiving dual blockade of PD1/PDL1 and CTLA4 in combination of anti-angiogenic treatment with or without other therapies Exclusion Criteria: ●Having malignancies in non-gastrointestinal system that have not been cured (Lynch syndrome not included)
Where this trial is running
Beijing, Beijing Municipality
- Jian Li — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Zhenghang Wang
- Email: zhenghang_wang@bjmu.edu.cn
- Phone: 18813186790
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.